Laboratorios (ROVI) | Stock Overview & Key Data
Laboratorios Farmaceuticos Rovi S.A. | Large-cap | Healthcare
Laboratorios Farmaceuticos Rovi S.A. | Large-cap | Healthcare
Laboratorios Performance Comparison
Stock Range
Today's Range
Low: €53.25
High: €53.90
on August 8, 2025
52 Week Range
Low: €45.52
High: €82.45
on April 9, 2025
on September 9, 2024
All-Time High: €94.80 on May 27, 2024
Explore how other Spanish stocks compare to their 52-week ranges: View ES Market 52-Week Insights
Key Statistics
Market Cap
€2.7B
EPS
2.59
P/E Ratio (TTM)
20.56
Forward P/E
19.65
P/B Ratio
4.83
PEG Ratio
19.65
Div. Yield
1.69%
ROE
25.01%
Beta
0.436
Debt to Equity
22.50
Financial Highlights
Profitability
Gross Margin
65.93%
Operating Margin
17.14%
Profit Margin
17.66%
Returns and Earnings
Return on Assets (TTM)
12.50%
Return on Equity (TTM)
25.01%
EBITDA
€301.6M
Net Income (TTM)
€132.3M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€14.64
Quarterly Revenue Growth (YoY)
-10.40%
Quarterly Earnings Growth (YoY)
-26.40%
Dividend Information
Last 12-Month Dividend
€0.94
Current Dividend Yield
1.69%
3-Year Average Dividend Yield
2.08%
3-Year Average Annual Dividend
€1.11
3-Year Total Dividends
€3.33
Ex-Dividend Date
July 14, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Laboratorios ROVI | 2.72B Large-cap | -2.03% | -3.37% | 3.41% | -4.32% | -17.03% | -32.16% | 1.36% | 86.38% |
| Almirall S.A ALM | 2.20B Large-cap | -3.21% | -4.12% | 0.20% | 13.15% | 22.20% | 14.03% | 4.28% | 7.11% |
| Faes Farma S.A FAE | 1.31B Large-cap | -3.21% | -5.80% | -0.24% | 15.30% | 20.23% | 19.89% | 7.11% | 21.97% |
| Laboratorio Reig RJF | 240.10M Mid-cap | 2.03% | 1.68% | 1.00% | 14.83% | 17.51% | 9.49% | 8.70% | -20.84% |
| Labiana Health S.A LAB | 28.16M Small-cap | 4.32% | 15.57% | 19.14% | 33.10% | 31.29% | 22.58% | 6,233.33% | 1,051.52% |
| Grifols, S.A GRF | 7.93B Large-cap | -2.06% | 22.50% | 57.28% | 54.08% | 35.84% | 46.52% | -6.61% | -47.55% |
Ownership & Short Interest
Insider Ownership
63.25%
Institutional Ownership
16.88%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
125K
Average 90-Day Volume
122K
Laboratorios Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Laboratorios would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is ROVI's 52-week high and low?
- In the last 52 weeks, Laboratorios reached a high of €82.45 (on September 9, 2024) and a low of €45.52 (on April 9, 2025).
- What is the market cap and P/E ratio for ROVI?
- Curious about Laboratorios's size and valuation? Its market capitalization stands at 2.72B. When it comes to valuation, the P/E ratio (trailing twelve months) is 20.56, and the forward P/E (looking ahead) is 19.65.
- Does ROVI pay dividends? If so, what's the yield?
- Yes, Laboratorios is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 1.69%, and the company has paid an average of €1.11 per share annually over the past 3 years.
- Who are Laboratorios's main competitors or similar companies to consider before investing?
When looking at Laboratorios, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Almirall S.A
ALM2.20B Healthcare Drug Manufacturers - Specialty & Generic 14.03% 4.28% Faes Farma S.A
FAE1.31B Healthcare Drug Manufacturers - Specialty & Generic 19.89% 7.11% Laboratorio Reig
RJF240.10M Healthcare Drug Manufacturers - Specialty & Generic 9.49% 8.70% Labiana Health S.A
LAB28.16M Healthcare Drug Manufacturers - Specialty & Generic 22.58% 6,233.33% Grifols, S.A
GRF7.93B Healthcare Drug Manufacturers - General 46.52% -6.61% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Laboratorios Farmaceuticos Rovi S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Laboratorios's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 25.01%, the Debt to Equity ratio from the most recent quarter is 22.50, and its Gross Profit Margin stands at 65.93%.
- What is the recent revenue and earnings growth for ROVI?
- Looking at Laboratorios's growth, its revenue over the trailing twelve months (TTM) was €749M. Compared to the same quarter last year (YoY), quarterly revenue grew by -10.40%, and quarterly earnings saw a YoY growth of -26.40%.
- How much of ROVI stock is held by insiders and institutions?
- Wondering who owns Laboratorios stock? Company insiders (like executives and directors) hold about 63.25% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 16.88%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.